Plain-English translation of NCT05389293 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new type of antibody drug that helps your immune system fight lymphoma cells. You'll either receive this medication alone, or combined with , a pill that targets cancer cells. Researchers want to see how well this medication works and how safe it is for people with newly diagnosed follicular lymphoma.
Follicular lymphoma is a blood cancer that often needs treatment when it's first diagnosed. While current treatments exist, doctors are looking for new options that might work better or cause fewer side effects. This trial is testing whether this medication can improve outcomes for newly diagnosed patients.
You likely qualify if…
You likely don't qualify if…
You will visit a cancer center regularly to receive the medication and be monitored for how well it works and any side effects. You may need to provide small tissue samples (biopsies) from your lymphoma before starting and a few weeks into treatment to help researchers understand how the medication is working. Depending on which group you're in, you'll either receive intravenous infusions of the antibody alone, or the antibody plus a daily pill—your doctor will discuss which approach is right for you.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States